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Thailand Thumbs Nose at USTR, Makes Affordable AIDS Treatment Top 
Priority
By Greg Lultschik
This piece was originally featured as a blog post at www.ipbrief.net. The AU Intellectual 
Property Brief provides daily content on hot issues, breaking news, and trends within 
intellectual property law worldwide.
Thailand is making waves on the international patent 
scene again with its plans to extend compulsory licensing 
schemes for Sustiva and Kaletra, two important HIV/
AIDS drugs.  With Thailand being a familiar face on the 
USTR’s 301 report and its prior scrap over this licensing 
plan with Kaletra owner Abbot Laboratories, the coun-
try seems to be willing to thumb its nose at the Trade 
Representative and the pharma giant’s significant influ-
ence. The decision came down after the Disease Control 
Department, the Depart-
ment of Intellectual Prop-
erty, the Foreign Ministry, 
the Government Pharmaceu-
tical Organization, the FDA, 
and several AIDS activist 
organizations agreed that the 
compulsory licensing policy 
was in accordance with the 
2001 Doha Declaration. For 
that many groups to reach 
a mutual agreement, my 
guess is that either some very 
good coffee was served at the 
meeting or that the represen-
tatives were told that lunch 
was conditional upon their 
reaching a conclusion.
In effect, the decision allows 
the Thai government to continue importing generic 
versions of the two drugs from India. With savings on 
AIDS drugs standing at $36 million since the licenses 
were imposed and $100 million in potential savings if 
the licenses are extended for the duration of the patents, 
the decision whether to maintain this policy has serious 
implications for access to HIV/AIDS treatment in Thai-
land. With the licenses in place, approximately 29,360 
people are receiving Sustiva and 6,200 have access to 
Kaletra. Before, only 4,539 people could get Sustiva 
and 39 could afford Kaletra. Yes, that’s 39 people out of 
a nation with an HIV+ population of almost 610,000. 
(http://www.bangkokpost.com/news/health/189154/
hiv-aids-drugs-licence-extended)
Some WCL students know that you can’t string together 
the words “Doha,” “Pharmaceuticals,” and “301 report” 
without attracting the attention of Professor Flynn over 
at the Program on Information Justice and Intellectual 
Property (PIJIP). Pro-
fessor Flynn and PIJIP 
covered this compulsory 
licensing issue extensive-
ly back in 2007, and the 
reports are still available 
here.  For some other PI-
JIP work on the Special 
301 report and access to 
medicines, check out the 
links below.
Review of the 2010 
Special 301 Report Sec-
tions on IP and Access to 
Medicines
http://www.wcl.
american.edu/pijip/go/
blog-post/preliminary-
review-of-the-2010-spe-
cial-301-report-sections-on-ip-and-access-to-medicines
PIJIP Calls for USTR Policy Change to Promote Access 
to Medicines:
http://www.wcl.american.edu/pijip/go/pijip03022010
